Iovance Biotherapeutics (IOVA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.11
- Estimate
- -$0.13
- Surprise
- +18.4%
- Revenue (period 2026-06-30)
- $99.3M
- Score at report (before → after)
- 5.4 → 6.5/10
Revenue source: xbrl.
How the report landed
Iovance Biotherapeutics (IOVA) reported a narrower loss than forecast — adjusted EPS of -$0.11 against the -$0.13 estimate (a 18.4% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Sell (5.4/10) to Buy (Wait) at 6.5/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates IOVA Sell at 5.6/10.
2 of the last 4 quarters beat the estimate; this quarter's +18.4% surprise compares with a -1.1% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: TILVANCE-301 (Amtagvi confirmatory Phase 3)
- Quality below floor (3.1 < 4.0)
- Value-trap signals (2/5): High leverage (D/E 3.9), Material insider selling (9 sells, 0.18% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $11.44
- Price target
- $12.53
- Stop
- $10.63
- Upside to target
- +9.6%
- Reward-to-risk
- 0.6:1
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
IOVA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $6.71B
- P/E (fwd)
- -75.7
- 52-week range
- $1.76–$15.37
- Off 52-week high
- 25.6%
- RSI (14)
- 32
- Volume vs avg
- 1.28×
- Score today
- 5.6/10